WO2014115087A3 - Procédé de préparation de prothrombine et de fibrinogène humains recombinants - Google Patents

Procédé de préparation de prothrombine et de fibrinogène humains recombinants Download PDF

Info

Publication number
WO2014115087A3
WO2014115087A3 PCT/IB2014/058465 IB2014058465W WO2014115087A3 WO 2014115087 A3 WO2014115087 A3 WO 2014115087A3 IB 2014058465 W IB2014058465 W IB 2014058465W WO 2014115087 A3 WO2014115087 A3 WO 2014115087A3
Authority
WO
WIPO (PCT)
Prior art keywords
recombinant human
fibrinogen
preparation
human prothrombin
coagulation factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2014/058465
Other languages
English (en)
Other versions
WO2014115087A2 (fr
Inventor
Kurt Osther
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CENCOR BIOTECH Ltd
Original Assignee
CENCOR BIOTECH Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CENCOR BIOTECH Ltd filed Critical CENCOR BIOTECH Ltd
Priority to RU2015135227A priority Critical patent/RU2015135227A/ru
Publication of WO2014115087A2 publication Critical patent/WO2014115087A2/fr
Publication of WO2014115087A3 publication Critical patent/WO2014115087A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001—Use of materials characterised by their function or physical properties
    • A61L24/0015—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/10—Polypeptides; Proteins
    • A61L24/106—Fibrin; Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/225—Fibrin; Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/418—Agents promoting blood coagulation, blood-clotting agents, embolising agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Surgery (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Materials Engineering (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne un procédé de production d'un facteur de coagulation humain. En particulier, le facteur de coagulation est produit dans une cellule hôte humaine. L'invention concerne également l'utilisation du facteur de coagulation humain recombinant en médecine.
PCT/IB2014/058465 2013-01-22 2014-01-22 Procédé de préparation de prothrombine et de fibrinogène humains recombinants Ceased WO2014115087A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2015135227A RU2015135227A (ru) 2013-01-22 2014-01-22 Способ получения рекомбинантного человеческого протромбина и фибриногена

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361849208P 2013-01-22 2013-01-22
US61/849,208 2013-01-22
US201361851801P 2013-03-13 2013-03-13
US61/851,801 2013-03-13

Publications (2)

Publication Number Publication Date
WO2014115087A2 WO2014115087A2 (fr) 2014-07-31
WO2014115087A3 true WO2014115087A3 (fr) 2014-10-30

Family

ID=50102145

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/058465 Ceased WO2014115087A2 (fr) 2013-01-22 2014-01-22 Procédé de préparation de prothrombine et de fibrinogène humains recombinants

Country Status (2)

Country Link
RU (1) RU2015135227A (fr)
WO (1) WO2014115087A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10900027B2 (en) 2015-10-09 2021-01-26 Cleveland State University Recombinant prothrombin analogues and uses thereof
EP3916009B1 (fr) * 2020-05-26 2023-06-28 Sartorius Lab Instruments GmbH & Co. KG Protéines recombinantes basées sur du fibrinogène
WO2025208342A1 (fr) * 2024-04-02 2025-10-09 苏州泽璟生物制药股份有限公司 Procédé de préparation de thrombine humaine recombinée de haute pureté et à faible résidu et utilisation associée

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1661989A1 (fr) * 2003-07-29 2006-05-31 Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute Procede pour preparer une cellule de recombinaison qui presente une grande capacite de production de fibrinogene et cellule presentant une grande capacite de production de fibrinogene
WO2007103447A2 (fr) * 2006-03-06 2007-09-13 Humagene, Inc. Procede de preparation de la thrombine recombinante humaine et du fibrinogene
DE102009003439A1 (de) * 2009-02-05 2010-08-26 Cevec Pharmaceuticals Gmbh Neue permanente humane Zelllinie

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4442655A (en) 1981-06-25 1984-04-17 Serapharm Michael Stroetmann Fibrinogen-containing dry preparation, manufacture and use thereof
ATE20824T1 (de) 1981-06-25 1986-08-15 Serapharm Gmbh & Co Kg Angereichertes plasmaderivat zur unterstuetzung von wundverschluss und wundheilung.
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
JPS6144825A (ja) 1984-08-09 1986-03-04 Unitika Ltd 止血剤
US4965203A (en) 1987-01-28 1990-10-23 Warner-Lambert Company Purified thrombin preparations
US5572692A (en) 1991-12-24 1996-11-05 Intel Corporation Memory configuration decoding system having automatic row base address generation mechanism for variable memory devices with row access interleaving
EP0624199B1 (fr) 1991-12-31 1999-05-06 Zymogenetics, Inc. Procedes de production de thrombine
US5527692A (en) 1991-12-31 1996-06-18 Zymogenetics, Inc. Methods for producing thrombin
US6780411B2 (en) 1998-05-01 2004-08-24 Zymogenetics, Inc. Tissue sealant compositions
DE102005054628A1 (de) 2005-11-16 2007-05-24 Cevec Pharmaceuticals Gmbh Verfahren zur Herstellung von permanenten humanen Zelllinien
WO2013007266A1 (fr) 2011-07-10 2013-01-17 Coloplast A/S Utilisation de la thrombine pour cicatriser les plaies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1661989A1 (fr) * 2003-07-29 2006-05-31 Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute Procede pour preparer une cellule de recombinaison qui presente une grande capacite de production de fibrinogene et cellule presentant une grande capacite de production de fibrinogene
WO2007103447A2 (fr) * 2006-03-06 2007-09-13 Humagene, Inc. Procede de preparation de la thrombine recombinante humaine et du fibrinogene
DE102009003439A1 (de) * 2009-02-05 2010-08-26 Cevec Pharmaceuticals Gmbh Neue permanente humane Zelllinie

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MARIA G. ROUBELAKIS ET AL: "Amniotic Fluid and Amniotic Membrane Stem Cells: Marker Discovery", STEM CELLS INTERNATIONAL, vol. 1, no. 1, 1 January 2012 (2012-01-01), pages 42 - 9, XP055111310, ISSN: 1687-966X, DOI: 10.1128/IAI.00643-07 *
SIMON FISCHER ET AL: "ARTICLE Transient Recombinant Protein Expression in a Human Amniocyte Cell Line: The CAP-T 1 Cell System", BIOTECHNOL. BIOENG, 1 January 2012 (2012-01-01), pages 2250 - 2261, XP055111266, Retrieved from the Internet <URL:http://onlinelibrary.wiley.com/store/10.1002/bit.24514/asset/24514_ftp.pdf?v=1&t=hth4zx74&s=6f41e7d8e53831e1f47db696e8f5c5d5436cea5a> [retrieved on 20140401] *

Also Published As

Publication number Publication date
WO2014115087A2 (fr) 2014-07-31
RU2015135227A (ru) 2018-12-25

Similar Documents

Publication Publication Date Title
IL288265A (en) Production and use of red blood cells
PH12015501703A1 (en) Trifluormethyl-substituted ring-fused pyrimidines and use thereof
WO2013151666A3 (fr) Polynucléotides modifiés destinés à la production de produits biologiques et de protéines associées à une maladie humaine
HK1206601A1 (en) Modified polynucleotides for the production of biologics and proteins associated with human disease
TN2015000434A1 (en) Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders
PH12014501595A1 (en) Substituted annulated pyrimidines and triazines, and use thereof
CL2015000084A1 (es) Célula huésped, particularmente de hongo filamentoso, deficiente en la producción de proteína agse; y método de producción de la célula.
BR112015004467A2 (pt) método para controlar a heterogeneidade de proteínas
WO2014151878A3 (fr) Procédés pour la modulation des profils de glycosylation de protéines de traitements à base de protéines recombinantes au moyen de monosaccharides et d&#39;oligosaccharides
WO2012106407A3 (fr) Procédés diagnostiques et thérapeutiques et produits liés aux troubles de l&#39;anxiété
MX2015006324A (es) Metodos para la fabricacion de polipeptidos proteoliticamente procesados.
BR112015013525A2 (pt) método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão
PH12014502496B1 (en) Bicyclically substituted uracils and the use thereof
PH12015500636A1 (en) Nutritional compositions including a calcium beta-hydroxy-beta-methylbutyrate, protein and low levels of electrolytes
AU2013359031A8 (en) Methods and apparatuses for making pasta filata
EA201600096A1 (ru) Бензил-1н-пиразол[3,4-b]пиридины и их применение
MD20150109A2 (ro) Construcţii proteice mitocondriale şi utilizările acestora
HUE045504T2 (hu) Kollagén és fibrin keveréket tartalmazó szövetragasztó, és eljárás annak elõállítására
HK1222325A1 (zh) 高效的胰酶藥物組合物
MX2016004250A (es) Tienouracilcarboxamidas ciclicas y usos de las mismas.
WO2014115087A3 (fr) Procédé de préparation de prothrombine et de fibrinogène humains recombinants
WO2013109190A3 (fr) Expression de protéine recombinante cho-gmt
AU2011301714B2 (en) Synthetic gene for expressing Sm-14 in Pichia pastoris, methods for producing and purifying Sm-14 and the use thereof as a vaccine and diagnostic medium
TN2014000085A1 (en) Substituted annellated pyrimidine and the use thereof
AU2013901871A0 (en) Inhalable rifapentine, methods of manufacture of the same, and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14704395

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2015135227

Country of ref document: RU

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 14704395

Country of ref document: EP

Kind code of ref document: A2